Humeral Augmented Tray (HAT) trials that are components of KIT-321HAT. Each tray contains 1 of ...

FDA Device Recall #Z-1977-2021 — Class II — May 11, 2021

Recall Summary

Recall Number Z-1977-2021
Classification Class II — Moderate risk
Date Initiated May 11, 2021
Status Completed
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Exactech, Inc.
Location Gainesville, FL
Product Type Devices
Quantity 36 devices

Product Description

Humeral Augmented Tray (HAT) trials that are components of KIT-321HAT. Each tray contains 1 of each of the following catalog numbers for a total of 6 trials/tray: (1) HAT STD Left Tray Trial, Cat. #321-00-01; (2) HAT STD Right Tray Trial, Cat. #321-00-02; (3) HAT LAT Left Tray Trial, Cat. #321-00-11; (4) HAT LAT Right Tray Trial, Cat. #321-00-12; (5) HAT EXT LAT Left Trial, Cat. #321-00-21; and (6) HAT EXT LAT Right Trial, Cat. #321-00-22. The Humeral Augmented Tray is designed to function with the Equinoxe Reverse Shoulder System orthopedic implant components.

Reason for Recall

The HAT trial contains a retaining ring that has shown the potential to disengage during use.

Distribution Pattern

US Nationwide distribution in the states of AZ, CO, FL, NY, SC, and TN. There was no foreign/government/military distribution.

Lot / Code Information

(1) HAT STD Left Tray Trial, Lot #279244001, UDI 10885862541239 ; (2) HAT STD Right Tray Trial, Lot #279244002, UDI 10885862541246 ; (3) HAT LAT Left Tray Trial, Lot #279244017, UDI 10885862541253; (4) HAT LAT Right Tray Trial, Lot #279244004, UDI 10885862541260; (5) HAT EXT LAT Left Trial, Lot #279244005, UDI 10885862541277; and (6) HAT EXT LAT Right Trial, Lot #279244006, UDI 10885862541284.

Other Recalls from Exactech, Inc.

Recall # Classification Product Date
Z-1509-2026 Class II Brand Name: Equinoxe Ergo Product Name: Ergo M... Feb 3, 2026
Z-1510-2026 Class II Brand Name: Equinoxe Product Name: Equinoxe C... Feb 3, 2026
Z-0536-2026 Class II Brand Name: Equinoxe Ergo Product Name: Adjust... Sep 5, 2025
Z-0537-2026 Class II Brand Name: Equinoxe Ergo Product Name: Ergo A... Sep 5, 2025
Z-0535-2026 Class II Brand Name: Equinoxe Ergo Product Name: Adjust... Sep 5, 2025

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.